Following monumental progress in 2023, the ALS treatment landscape is surging with novel innovation to navigate the complex, multifactorial nature of motor neuron degeneration and develop more truly transformative drugs for sporadic and familial ALS.
Capitalizing on rapid pipeline progress and emerging industry investment, the 3rd Annual ALS Drug Development Summit returns to Boston, providing a comprehensive breakdown of the latest motor neuron models, biomarker strategies, approval insights, and novel approaches to target the likes of TDP-43, STMN2, and PIKfyve. Engage in forward-thinking discussions and gain fresh perspectives on the most meaningful endpoints and trial design considerations for people living with ALS.
This May, join your industry colleagues across discovery, preclinical, clinical, regulatory, and commercial from the likes of Biogen, AbbVie, NeuroSense, Mitsubishi, Sanofi, Takeda, Novartis, and more.
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Hear from your 2024 Speakers:
“A great summit to connect Preclinical and Clinical thought leaders on ALS and to garner recent progress for breakthrough ALS therapies.”
Mansuo Lu Shannon, Chief Scientific Officer, Prevail Therapeutics
“ALS Summit brings together experts across basic scientific research, biotech, pharma, patient advocacy groups to the same room for vibrant and engaged discussions. The program captures the key progress and development in the field as well as emerging technologies and science, but still nimble and focused not to overwhelm the attendees!”
Fen Haung, Director, Translational Medicine, Denali